 |
53 Diseases |  |
17 Trials |
|
17 Trials |  |
785 News |  |
| «12...345678910111213...1415» |
- | Adempas (riociguat) / Bayer
Preclinical, Journal: Riociguat, sildenafil and inhaled nitric oxide reduces pulmonary vascular resistance and improves right ventricular function in a porcine model of acute pulmonary embolism. (Pubmed Central) - Apr 28, 2021
Systemic blood pressure was unaltered in all treatment groups. Stimulation of the NO-sGC-cGMP pathway by riociguat, sildenafil and inhaled NO reduces pulmonary vascular resistance in a porcine model of acute pulmonary embolism without lowering systemic blood pressure.
- || Adempas (riociguat) / Bayer
Review, Journal: Chronic Thromboembolic Pulmonary Hypertension-Management Strategies and Outcomes. (Pubmed Central) - Apr 28, 2021
Endothelin receptor antagonists serve a supplemental role postoperatively or in inoperable CTEPH. The role of drug therapy preoperatively or in tandem with BPA is currently under investigation.
- | Adempas (riociguat) / Bayer
Journal: How should a physician approach the pharmacological management of chronic thromboembolic pulmonary hypertension? (Pubmed Central) - Apr 28, 2021
Additionally, anticoagulation therapy is also a substantial medical treatment in all CTEPH patients without contradiction. However, the benefit-to-risk balance in life-long anticoagulation and whether more individualized anticoagulation strategies are needed warrants further investigation.
- | Adempas (riociguat) / Bayer
Journal: Evolving spectrum of treatment for CTEPH. (Pubmed Central) - Apr 27, 2021
Recent publications provide a wealth of data on safety and efficacy of BPA for inoperable subsegmental disease, but its precise fit in the treatment algorithm, both pharmacological and procedural, requires further investigation. PTE remains the procedure of choice for surgically accessible disease.
- Adempas (riociguat) / Bayer, Tracleer (bosentan) / J&J, Roche
[VIRTUAL] According to recent ACC/AHA guidelines for management of PH associated with Eisenmenger syndrome, which currently approved medication is given a Class I recommendation for medical treatment of this condition? A: Epoprostenol; B. Tadalafil; C. Bosentan; D. Riociguat (Global Channel) - Apr 20, 2021 - Abstract #ACC2021ACC_9228;
PTE remains the procedure of choice for surgically accessible disease. There is no abstract associated with this presentation.
- | Verquvo (vericiguat) / Bayer, Merck (MSD)
Journal: Vericiguat (Verquvo) for heart failure. (Pubmed Central) - Apr 15, 2021
There is no abstract associated with this presentation. No abstract available
- Adempas (riociguat) / Bayer
[VIRTUAL] A Disproportionality Analysis of Spontaneous Adverse Event Reports for PAIN in Jaw Attributed to Riociguat in FDA Adverse Events Reporting System (FAERS) () - Apr 12, 2021 - Abstract #ISPOR2021ISPOR_952;
Although a causal relation cannot be definitively proved, the number of cases reported suggests that there might be an association. Increased awareness of this risk among both prescribers and patients may help mitigate the number and severity of these adverse events.
- [VIRTUAL] EFFECTS OF FACE-TO-FACE EDUCATIONAL NURSING SUPPORT ON PATIENT COMPLIANCE WITH ORAL PAH THERAPIES () - Apr 11, 2021 - Abstract #AMCP2021AMCP_128;
Patients receiving oral PAH therapies in an educational nursing program demonstrated a positive effect on overall medication compliance as demonstrated by a statistically significant improvement in MPR and therapy persistence. While our study compared two different PAH therapy classes, a multidisciplinary patient support approach contributed to improved patient outcomes.
- || Adempas (riociguat) / Bayer
Thanks! Had to refresh my knowledge on Adempas 🤣 Any utility to anticoagulant/antiplatelet after plasty? (Twitter) - Apr 6, 2021
- |||| Adempas (riociguat) / Bayer
Clinical: Thanks. Multidisciplinary CTEPH team which includes pulmonologists, cardiologists, CT surg and IR. Most patients are on adempas and get weaned off after 4-6 sessions of BPA depending on treatment success. (Twitter) - Apr 6, 2021
- | Adempas (riociguat) / Bayer
Journal: Sensitive CE-MS method for monitoring of riociguat and desmethylriociguat levels in human serum. (Pubmed Central) - Apr 2, 2021
Clinical applicability was validated using serum samples from patients treated with riociguat in pharmacokinetic study and the results corresponded with reference HPLC-MS/MS values. Capillary electrophoresis proved to be sensitive and selective tool for the analysis of riociguat and DMR.
- | Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open: REPO-STROKE1: Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers (clinicaltrials.gov) - Mar 26, 2021
P1, N=8, Recruiting, Sponsor: Maastricht University
Capillary electrophoresis proved to be sensitive and selective tool for the analysis of riociguat and DMR. Not yet recruiting --> Recruiting
- |||||| Adempas (riociguat) / Bayer, Merck (MSD)
New trial, Real-world evidence, Real-world: ROAR: A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH) (clinicaltrials.gov) - Mar 23, 2021
P, N=500, Not yet recruiting, Sponsor: Bayer
- || Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Clinical, Review, Combination therapy: Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia (Pubmed Central) - Mar 23, 2021
Some beneficial pharmacological effects due to the synergy between ambrisentan plus riociguat, and inhaled iloprost plus sildenafil appear to be interesting and require further clinical confirmation. Other initial combinations of PAH-specific agents require large-scale clinical trials as well.
- | Adempas (riociguat) / Bayer
Preclinical, Journal: Riociguat ameliorates kidney injury and fibrosis in an animal model. (Pubmed Central) - Mar 17, 2021
Furthermore, administration of RIO reduced expression of collagen-1, TGF-β, CTGF, α-SMA, vimentin along with transcription factors including Snail and Slug. The results of the present study provided strong evidence to support the antifibrotic activity of RIO.
- Adempas (riociguat) / Bayer
[VIRTUAL] Assessing the Suitability of Treatment with Riociguat in Pulmonary Hypertension Patients with End Stage Renal Disease () - Mar 14, 2021 - Abstract #ATS2021ATS_4406;
The primary objective was to evaluate the metric parameters of disease severity as outlined by the ESC/ERS 2015 guidelines. Although our favorable findings cannot be generalized to the entire ESRD population, they suggest the need for more robust trials on the use of Riociguat in this cohort.
- Adempas (riociguat) / Bayer
[VIRTUAL] Riociguat Was Effective in Increasing Time until Clinical Worsening in Sarcoidosis Associated Pulmonary Hypertension: Results of a One Year Double Blind, Placebo Controlled Trial () - Mar 14, 2021 - Abstract #ATS2021ATS_4110;
Although our favorable findings cannot be generalized to the entire ESRD population, they suggest the need for more robust trials on the use of Riociguat in this cohort. Over the one year of the study, riociguat was effective in preventing clinical worsening and improving exercise capacity in patients with SAPH.
- Adempas (riociguat) / Bayer
[VIRTUAL] Switching to Riociguat from Phosphodiesterase-5 Inhibitors, With or Without Endothelin Receptor Antagonists, in Patients with Pulmonary Arterial Hypertension: Results from the REPLACE Study () - Mar 14, 2021 - Abstract #ATS2021ATS_3236;
For patients with PAH receiving PDE5i monotherapy or combined PDE5i+ERA at baseline, achievement of the primary endpoint was consistent with results in the overall population. Switching to riociguat can serve as a strategic option for treatment escalation in patients at intermediate risk receiving treatment with PDE5i alone or in combination with an ERA.
- Adempas (riociguat) / Bayer
[VIRTUAL] Riociguat Should Be Given to All CTEPH Patients, Regardless of Timing of PEA () - Mar 14, 2021 - Abstract #ATS2021ATS_2322;
- Adempas (riociguat) / Bayer
[VIRTUAL] Riociguat Should Be Given Only to Patients with Inoperable or Residual CTEPH After Surgical Pulmonary Thromboendarterectomy () - Mar 14, 2021 - Abstract #ATS2021ATS_1499;
- Adempas (riociguat) / Bayer
[VIRTUAL] BPA and Riociguat for the Management of Inoperable CTEPH: Results of the Extension Study Following the RACE Randomized Controlled Trial (RCT) () - Mar 14, 2021 - Abstract #ATS2021ATS_705;
P=N/A
The extension study indicates that the decrease in PVR at 1 year was similar regardless of the first-line treatment that was used (BPA or riociguat). In addition, the incidence of SAE related to BPA was much lower when BPA was preceded by a 6-month treatment with riociguat as compared to BPA 1st line.
- || Adempas (riociguat) / Bayer, Uptravi (selexipag) / J&J, Nippon Shinyaku, Opsumit (macitentan) / Nippon Shinyaku, J&J
Clinical, Journal, Combination therapy: Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study) - Protocol of a Multicenter Randomized Control Trial. (Pubmed Central) - Mar 12, 2021
In addition, the incidence of SAE related to BPA was much lower when BPA was preceded by a 6-month treatment with riociguat as compared to BPA 1st line. The SETOUCHI-PH study will clarify whether initial combination therapy with macitentan plus riociguat or macitentan plus selexipag results in equal reductions in PVR 8 months after administration.
- || Adempas (riociguat) / Bayer
Review, Journal: Balloon Pulmonary Angioplasty: State of the Art. (Pubmed Central) - Mar 6, 2021
This article aims to provide the reader with an overview of BPA, starting with an introduction to chronic thromboembolic disease (CTED), the standard management of chronic thromboembolic pulmonary hypertension (CTEPH), technical challenges faced when performing BPA and the evidence base supporting its use. The second part of the article will focus on the future of BPA, in particular the areas where research is required to establish an evidence base to justify the role of BPA in CTEPH and CTED treatment.
- | Adempas (riociguat) / Bayer
Preclinical, Journal: Stimulation of Soluble Guanylate Cyclase Diminishes Intrauterine Growth Restriction in a Rat Model of Placental Ischemia. (Pubmed Central) - Mar 2, 2021
Yet, UARI (p<0.001), proportional junctional zone surface area (p=0.013), and placental hFABP protein expression (p=0.008) were increased in sGC-treated Sham suggesting a potential adverse effect of Riociguat. Collectively, these results suggest sGC contributes to IUGR in PE.
- | Adempas (riociguat) / Bayer, Merck (MSD)
New P1 trial: REPO-STROKE1: Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers (clinicaltrials.gov) - Feb 28, 2021
P1, N=8, Not yet recruiting, Sponsor: Maastricht University
- | Adempas (riociguat) / Bayer
Journal: Soluble Guanylate Cyclase Stimulators and Activators. (Pubmed Central) - Feb 26, 2021
Now, 20 years later, the stimulator of soluble guanylate cyclase (sGC), riociguat, is on the market and is the only drug approved for the treatment of two forms of pulmonary hypertension (PAH/CTEPH), and a variety of other sGC stimulators and sGC activators are in preclinical and clinical development for additional indications...Finally, the clinical developments, investigating the treatment potential of these compounds in various diseases like heart failure, diabetic kidney disease, fibrotic diseases, and hypertension, are reported. In summary, sGC stimulators and sGC activators have a unique mode of action with a broad treatment potential in cardiovascular diseases and beyond.
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Journal: The Cell Cycle Checkpoint System MAST(L)-ENSA/ARPP19-PP2A is Targeted by cAMP/PKA and cGMP/PKG in Anucleate Human Platelets. (Pubmed Central) - Feb 20, 2021
Low-dose OA treatment of platelets caused PP2A inhibition, diminished thrombin-stimulated platelet aggregation and increased phosphorylation of distinct sites of VASP, Akt, p38 and ERK1/2 MAP kinases. In summary, our data establish the entire MASTL(like)-ENSA/ARPP19-PP2A pathway in human platelets and important interactions with the PKA, MAPK and PI3K/Akt systems.
- Adempas (riociguat) / Bayer, Tracleer (bosentan) / J&J, Roche
[VIRTUAL] According to recent ACC/AHA guidelines for management of PH associated with Eisenmenger syndrome, which currently approved medication is given a Class I recommendation for medical treatment of this condition? A: Epoprostenol; B. Tadalafil; C. Bosentan; D. Riociguat (Global Channel) - Feb 17, 2021 - Abstract #ACC2021ACC_1464;
In summary, our data establish the entire MASTL(like)-ENSA/ARPP19-PP2A pathway in human platelets and important interactions with the PKA, MAPK and PI3K/Akt systems. There is no abstract associated with this presentation.
- Verquvo (vericiguat) / Bayer, Merck (MSD), Adempas (riociguat) / Bayer, praliciguat (IW-1973) / Cyclerion
[VIRTUAL] SAFETY AND EFFICACY OF SOLUBLE GUANYLATE CYCLASE STIMULATORS IN PATIENTS WITH HEART FAILURE (eAbstract site) - Feb 17, 2021 - Abstract #ACC2021ACC_960;
Digital databases were queried to identify relevant RCT. The use of sGC stimulators in conjunction with the standard HF therapy might decrease the overall incidence of heart failure-related hospitalization with no overall increase in the net adverse events.
- || Adempas (riociguat) / Bayer
Clinical, Journal: Pulmonary Artery Denervation for Patients With Residual Pulmonary Hypertension After Pulmonary Endarterectomy. (Pubmed Central) - Feb 2, 2021
The use of sGC stimulators in conjunction with the standard HF therapy might decrease the overall incidence of heart failure-related hospitalization with no overall increase in the net adverse events. PADN in patients with residual CTEPH resulted in substantial reduction of PVR at 12 months of follow-up, accompanied by improved 6-min walk test.
- ||| Adempas (riociguat) / Bayer
Thanks, @GRamaniMD for your talk on PHTN for @UMdPCCM fellows! Key points: -Definition mPAP >20 mm Hg -Vasodilator challenge is recommended for idiopathic and hereditary (BMPR2 gene) PAH. Positive = mPAP ↓to <40, with fall >10, with ↔/↑ CO -Riociguat used for inoperable CTEPH (Twitter) - Feb 1, 2021
- ||| Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion, Trial completion date, Trial primary completion date: RACE: Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension (clinicaltrials.gov) - Jan 26, 2021
P=N/A, N=105, Completed, Sponsor: Assistance Publique - H
PADN in patients with residual CTEPH resulted in substantial reduction of PVR at 12 months of follow-up, accompanied by improved 6-min walk test. Recruiting --> Completed | Trial completion date: Sep 2019 --> Jan 2020 | Trial primary completion date: Sep 2019 --> Jan 2020
- || Adempas (riociguat) / Bayer, Tyvaso (treprostinil) / United Therapeutics Corp, Opsumit (macitentan) / Nippon Shinyaku, J&J
Review, Journal: Interventional and pharmacological management of chronic thromboembolic pulmonary hypertension. (Pubmed Central) - Jan 20, 2021
Riociguat is currently the only medical therapy licensed for treatment of inoperable or persistent/recurrent CTEPH after PEA based on the results of the Phase III CHEST-1 study...Studies of macitentan in patients with inoperable CTEPH and treprostinil in patients with inoperable or persistent/recurrent CTEPH showed positive results...In the future, CTEPH may be managed by PEA, medical therapy or BPA - alone or in combination, according to individual patient needs. Patients should be referred to experienced centers capable of assessing and delivering all options.
- || Adempas (riociguat) / Bayer
Clinical, Journal: Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. (Pubmed Central) - Jan 11, 2021
Patients should be referred to experienced centers capable of assessing and delivering all options. Final data from EXPERT show that in patients with PAH, the safety of riociguat in clinical practice was consistent with clinical trials, with no new safety concerns identified and a lower exposure-adjusted rate of hemoptysis/pulmonary hemorrhage than in the long-term extension of the Phase 3 trial in PAH.
- | Adempas (riociguat) / Bayer
Journal: Discovery of Novel Pyrazolo[3,4-b] pyridine Derivatives with Dual Activities of Vascular Remodeling Inhibition and Vasodilation for the Treatment of Pulmonary Arterial Hypertension. (Pubmed Central) - Jan 9, 2021
In vivo, 2 significantly decreased right ventricular systolic pressure (RVSP), attenuated pulmonary artery medial thickness (PAMT) and right ventricular hypertrophy (RVH) in hypoxia-induced PAH rat models (i.g.). Given the unique advantages of significant vascular remodeling inhibition and moderate vascular relaxation based on dual pathways regulation, we proposed 2 as a promising lead for anti-PAH drug discovery.
- | Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion date, Trial primary completion date: A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases (clinicaltrials.gov) - Jan 8, 2021
P2, N=100, Recruiting, Sponsor: Mark Gladwin
Given the unique advantages of significant vascular remodeling inhibition and moderate vascular relaxation based on dual pathways regulation, we proposed 2 as a promising lead for anti-PAH drug discovery. Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
- | vericiguat (BAY 1021189) / Bayer, Merck (MSD), Adempas (riociguat) / Bayer, praliciguat (IW-1973) / Cyclerion
Journal: cGMP: a unique 2nd messenger molecule - recent developments in cGMP research and development. (Pubmed Central) - Jan 6, 2021
This review tries to summarize the contributions to the "9th International cGMP Conference on cGMP Generators, Effectors and Therapeutic Implications" held in Mainz in 2019. Presented data will be discussed and extended also in light of recent landmark findings and ongoing activities in the field of preclinical and clinical cGMP research.
- || Review, Journal: Soluble guanylate cyclase stimulators and their potential use: a patent review. (Pubmed Central) - Jan 5, 2021
Expert Opinion: With the recent advancements reported in the patent literature, sGC stimulators might be differentiated due to tissue selectivity or route of application although exhibiting the same molecular mode of action. The indication space of these compounds is potentially very broad and multiple indications in cardiovascular diseases and beyond are under investigation.
- || Adempas (riociguat) / Bayer
Clinical, Review, Journal: Pulmonary Hypertension: A Brief Guide for Clinicians. (Pubmed Central) - Jan 2, 2021
The soluble guanylate cyclase stimulator riociguat is the only licensed targeted therapy for patients with inoperable or persistent/recurrent CTEPH. Management of PH resulting from left-sided heart disease primarily involves treatment of the underlying condition.
- || Adempas (riociguat) / Bayer
Clinical, Journal: Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study. (Pubmed Central) - Dec 30, 2020
Achievement of the composite endpoint at Week 12 was associated with a 45% reduction in relative risk of death and a 19% reduction in relative risk of clinical worsening in PATENT-2. Overall, these data suggest that use of the REPLACE composite endpoint in patients with pulmonary arterial hypertension is a valid assessment of response to treatment.
- Adempas (riociguat) / Bayer, Opsumit (macitentan) / Nippon Shinyaku, J&J, Tracleer (bosentan) / J&J, Roche
[VIRTUAL] Assessment of system-wide hospital compliance with inpatient oral pulmonary hypertension Risk Evaluation and Mitigation Strategies programs () - Dec 26, 2020 - Abstract #ASHP2020ASHP_1807;
During June 2020, AdventHealth Orlando was selected to participate in an audit reviewing compliance with the newly developed shared ambrisentan REMS...Further evaluation of inpatient compliance is required of all oral pulmonary hypertension medication REMS programs including bosentan, macitentan, and riociguat...All patients that meet the inclusion criteria will be included in the analysis. Compliance with required REMS criteria and appropriate documentation per institutional policies will be evaluated for selected agents.
- | Adempas (riociguat) / Bayer
Journal: The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat (Pubmed Central) - Dec 22, 2020
Switching from PDE-5 to riociguat may be safe and appropriate, according to clinical trials presented in the review. In accordance with the guidelines for the diagnosis and treatment of pulmonary hypertension of the Eurasian Association of cardiologists from 2019, this strategy is approved when PDE5 therapy is ineffective in patients with PAH FC III (WHO).
- | Adempas (riociguat) / Bayer
Preclinical, Journal: Stimulation of soluble guanylate cyclase improves donor organ function in rat heart transplantation. (Pubmed Central) - Dec 20, 2020
Pharmacological preconditioning with riociguat decreases ischemia-reperfusion injury and improves donor organ function in our animal model of heart transplantation. Therefore, riociguat might be a potential cardioprotective agent.
- || Adempas (riociguat) / Bayer
Clinical, Journal: Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. (Pubmed Central) - Dec 17, 2020
Adherence to oral disease-specific treatment was 60-66% and associated with time since diagnosis and number of concomitant chronic treatments. Sex, age or socioeconomic factors did not affect adherence.
- || metformin / Generic mfg., fluconazole / Generic mfg.
Review, Journal: A minireview of pharmacologic strategies used to ameliorate polyuria associated with X-linked nephrogenic diabetes insipidus. (Pubmed Central) - Dec 16, 2020
It is concluded that there is currently no established intervention that causally improves symptoms and quality of life in patients with NDI. There is a need to collaborate to improve study quality and conduct formal trials.
- | Adempas (riociguat) / Bayer
Journal: Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies. (Pubmed Central) - Dec 8, 2020
In conclusion, riociguat improved pulmonary arterial compliance in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Pulmonary arterial compliance at baseline or follow-up, rather than change in pulmonary arterial compliance, is of prognostic importance for outcomes.
- || Adempas (riociguat) / Bayer
Clinical, Journal: Successful Transition from Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study. (Pubmed Central) - Nov 28, 2020
Transition from a PDE5i to riociguat without a washout period is safe. This transition may be a viable option for patients with headaches caused by a PDE5i, or who have an inadequate response to combination therapy that includes a PDE5i.
- | Adempas (riociguat) / Bayer
Journal: Protective role of endothelial progenitor cells stimulated by riociguat in chronic thromboembolic pulmonary hypertension. (Pubmed Central) - Nov 25, 2020
This transition may be a viable option for patients with headaches caused by a PDE5i, or who have an inadequate response to combination therapy that includes a PDE5i. These findings indicate that riociguat may induce EPCs to play a protective role via modulation of endothelial functions associated with CTEPH.
- || Adempas (riociguat) / Bayer, cinaciguat (BAY 58-2667) / Bayer
Clinical, Journal: Inhaled nitric oxide to control platelet hyper-reactivity in patients with acute submassive pulmonary embolism. (Pubmed Central) - Nov 25, 2020
In patients with acute submassive PE, despite evidence of adequate drug delivery, inhaled NO had no major effect on platelet O2 consumption or agonist-stimulated parameters on TEG. Pharmacological activation, but not stimulation, of sGC effectively decreased platelet cytosolic [Ca], and platelet sGC activity was increased with PE, confirming the viability of sGC as a therapeutic target.
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD), Adempas (riociguat) / Bayer
Retrospective data, Review, Journal: Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis. (Pubmed Central) - Nov 14, 2020
Pharmacological activation, but not stimulation, of sGC effectively decreased platelet cytosolic [Ca], and platelet sGC activity was increased with PE, confirming the viability of sGC as a therapeutic target. The use of vericiguat and riociguat in conjunction with standard HF therapy, shows no benefit in terms of decreasing HF-related hospitalizations or mortality.